Aflibercept misses endpoint in mid-stage study

Regeneron and Sanofi-Aventis announced that their experimental therapy aflibercept missed a mid-stage goal for an ovarian cancer trial. The primary goal was a five percent response for established criteria at two dosages. At the higher dose, researchers tracked a 4.5 percent response and a 0.9 percent response at the lower dose.

Aflibercept is also being tested in late-stage trials for prostate, colorectal, pancreatic and non-small cell lung cancers. Both companies say they're now evaluating how to proceed developing the therapy.

- take a look at the announcement
- read the AP story

Related Articles:
Sanofi snags bigger stake, new pact with Regeneron
Sanofi, Regeneron launch late-stage cancer studies
Regeneron wins rich pact for VEGF trap

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.